Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a
Bruton's Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell
malignancies